reviewed april 2026|next review october 2026|88 physicians psi has verified|1 published studies
IGF-1 DES
IGF-1 DES (des(1-3)IGF-1) is a 67-amino-acid truncated variant of IGF-1 with approximately 10-fold greater potency in cell proliferation assays due to dramatically reduced binding to IGF-binding proteins, raising significant safety concerns from unregulated mitogenic signaling.
Evidence landscape: 1 published studies
Limited published studies under this specific slug.
- 1 Other research
Not FDA-approved. Not in clinical development. No Investigational New Drug application has been filed. Developed as a laboratory research reagent for studying IGF-1 receptor signaling, not as a therapeutic agent.
Available as a research reagent from laboratory suppliers. Not legally marketed for human use. Not available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.
IGF-1 DES is a truncated variant of native IGF-1 with the first three amino acids removed. This eliminates binding protein capture, producing approximately 10-fold greater potency at the IGF-1 receptor. The resulting unregulated IGF-1R signaling carries significant theoretical cancer risk.
PSI Assessment
The evidence profile for IGF-1 DES is defined by a paradox: it is approximately ten times more potent than native IGF-1 at the receptor level, yet it has zero published human clinical data and was never designed for therapeutic use. IGF-1 DES (Des(1-3)IGF-1) is a truncated variant of insulin-like growth factor 1 with the first three amino acids removed, which eliminates binding protein capture and dramatically increases receptor potency. It is primarily used as a laboratory research reagent for studying acute IGF-1 receptor signaling. It has never been approved by any regulatory body. The biochemistry is well-characterized, the cell culture utility is established, and the biohacking community has extrapolated laboratory properties into therapeutic claims. But the gap between a validated research tool and a safe human therapeutic is one of the widest in the peptide space. Here is what the published research actually supports.
Approximately 10-fold greater potency than full-length IGF-1. Less than 1% IGFBP binding affinity. Unregulated IGF-1 signaling is strongly associated with tumor proliferation.
The mechanism centers on the removal of the N-terminal tripeptide (Gly-Pro-Glu) from native IGF-1. This three-amino-acid sequence is the primary binding domain for IGF-binding proteins (IGFBPs 1-6), which normally sequester 95-99% of circulating IGF-1. Without IGFBP capture, IGF-1 DES has dramatically increased bioavailability at the IGF-1 receptor (IGF-1R). Receptor binding affinity is similar to native IGF-1, but the effective potency is approximately 10-fold higher because the free fraction is not regulated by the binding protein system. IGF-1R activation drives two primary signaling cascades: PI3K/Akt/mTOR (promoting cell survival and protein synthesis) and Ras/MAPK/ERK (promoting cell proliferation). In native physiology, IGFBPs serve as a buffering system controlling the magnitude and duration of IGF-1R activation. By eliminating IGFBP binding, IGF-1 DES produces acute, unregulated receptor activation. This is pharmacologically useful in cell culture experiments but raises serious safety concerns in vivo: unregulated IGF-1R activation is associated with increased cancer risk in epidemiological studies of the body's own IGF-1 levels.
What the evidence supports
Des(1-3)IGF-1 has approximately 10-fold greater potency than native IGF-1 in cell proliferation assays due to reduced IGFBP binding (less than 1% of native affinity). The truncation removes the N-terminal tripeptide responsible for IGFBP interaction. The resulting unregulated IGF-1R signaling is pharmacologically characterized.
What is not yet established
Controlled human studies of any kind. Whether the increased potency in cell assays translates to proportionally greater in vivo effects. Quantification of the tumor promotion risk from unregulated IGF-1R signaling. Long-term safety profile. Whether IGF-1 DES offers any therapeutic advantage over regulated IGF-1 analogs.
Research Evidence
The findings below cover the established receptor pharmacology and the critical gap between cell culture utility and any therapeutic claim.
Evidence by condition
Evidence dimensions available for each condition IGF-1 DES has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cell Proliferation Research | ||||
| Muscle Hypertrophy | ||||
| Cancer Risk Research |
Des(1-3)IGF-1 has approximately 10-fold greater potency than native IGF-1 in cell proliferation assays. The truncation removes the N-terminal tripeptide responsible for IGFBP interaction, reducing binding affinity to less than 1% of native IGF-1.
This is well-established cell culture science. The potency increase does not imply therapeutic utility. It reflects elimination of the regulatory system that normally controls IGF-1 activity.
How IGF-1 DES Works
IGF-1 DES is a 67-amino-acid truncated variant of insulin-like growth factor 1. The removal of the N-terminal tripeptide (Gly-Pro-Glu) eliminates binding to IGF-binding proteins (IGFBPs 1-6), which normally sequester 95-99% of circulating IGF-1.
The body produces IGF-1 (insulin-like growth factor 1), a hormone that tells cells to grow and repair. Normally, IGF-1 is regulated by binding proteins that control how much of it is active at any given time. IGF-1 DES has been modified to slip past those binding proteins, meaning it activates growth signals approximately 10 times more powerfully than the natural version. This was designed to be useful in laboratory experiments studying cell growth, not as a medication.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
IGF-1 DES lacks the N-terminal tripeptide (Gly-Pro-Glu) present in native IGF-1. This region is the primary binding domain for IGF binding proteins (IGFBPs 1-6), which normally sequester 95-99% of circulating IGF-1. Without IGFBP capture, IGF-1 DES has dramatically increased bioavailability at the IGF-1 receptor (IGF-1R). Receptor binding affinity is similar to native IGF-1, but the effective potency is approximately 10-fold higher because the free fraction is not regulated by the binding protein system.
What is IGF-1 DES being studied for?
Researchers are studying IGF-1 DES across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for IGF-1 DES overall. This means a compound can have human studies for one condition but only animal data for another.
Cell Proliferation Research
·PreclinicalIGF-1 DES is a validated cell culture reagent for studying IGF-1 receptor signaling. The approximately 10-fold potency increase over native IGF-1 makes it useful for experiments requiring robust IGF-1R activation without the confounding variable of IGFBP regulation.
Limitations: Cell culture utility does not imply clinical utility. No published human or animal efficacy studies for any therapeutic indication.
Muscle Hypertrophy
·PreclinicalIGF-1 receptor activation promotes muscle protein synthesis through the PI3K/Akt/mTOR pathway. The biohacking community uses IGF-1 DES for localized muscle growth based entirely on extrapolation from receptor pharmacology.
Limitations: Zero published evidence for muscle growth in any model system. The entire use case is extrapolated from general IGF-1 receptor biology. Pharmacokinetics of localized injection are unknown.
Cancer Risk Research
·PreclinicalUnregulated IGF-1R activation promotes cell proliferation and survival. Epidemiological data links elevated IGF-1 levels to increased cancer incidence. IGF-1 DES bypasses the binding protein system that normally regulates IGF-1 activity.
Limitations: The cancer risk from IGF-1 DES specifically has not been quantified. Theoretical risk is based on general IGF-1R signaling biology.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication. Not in clinical development. No Investigational New Drug application has been filed. Available as a research reagent from laboratory suppliers.
Availability: Not legally marketed for human use. Available from research peptide suppliers and laboratory reagent companies.
Class context: IGF-1 DES is a truncated IGF-1 variant. The primary theoretical concern is cancer risk from unregulated IGF-1 receptor activation. Epidemiological data links elevated IGF-1 signaling to increased cancer incidence.
No human safety data exists for IGF-1 DES. It was developed as a laboratory research reagent, not as a therapeutic agent. The primary theoretical concern is cancer risk: IGF-1 receptor activation promotes cell proliferation and survival, and epidemiological data links elevated IGF-1 levels to increased cancer incidence. By bypassing the binding protein system that normally regulates IGF-1 activity, IGF-1 DES delivers unregulated growth factor signaling.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a IGF-1 DES discussion.
Comparison and Related Research
IGF-1 DES sits within the IGF-1 variant family. Understanding the differences between modified IGF-1 forms clarifies the risk-benefit profile.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Characterized des(1-3)IGF-I and other IGF-I analogs, demonstrating that removing the first three amino acids from IGF-I significantly reduced binding to IGF binding proteins while preserving receptor affinity. This explained why des(1-3)IGF-I shows enhanced biological potency compared to full-length IGF-I.Francis GL et al., 1992 in J Mol Endocrinol. View on PubMed
- 2.Comprehensive review of des(1-3)IGF-I biology, covering the structural difference from full-length IGF-I, the dramatically reduced binding to IGF binding proteins, and the resulting increase in bioavailability. This paper established the pharmacological rationale for studying the truncated variant.Ballard FJ et al., 1996 in Int J Biochem Cell Biol. View on PubMed
- 3.Demonstrated that IGF binding proteins inhibited the biological activity of full-length IGF-I and IGF-II but did not inhibit des(1-3)IGF-I. This was a key early finding establishing that the truncated variant bypasses the regulatory system that normally limits IGF-I activity in tissues.Ross M et al., 1989 in Biochem J. View on PubMed
- 4.Extended the structural understanding of IGF peptide variants by examining how N-terminal modifications alter binding characteristics. The study confirmed that truncation of the N-terminal region selectively reduces binding protein interactions while maintaining receptor binding capacity.Francis GL et al., 1993 in Biochem J. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.